Navigation Links
Johnson & Johnson Files Arbitration Demand Against Schering-Plough to Resolve Dispute Over Agreements for REMICADE(R) and SIMPONI(TM)
Date:5/27/2009

NEW BRUNSWICK, N.J., May 27 /PRNewswire-FirstCall/ -- In an arbitration demand filed today with the American Arbitration Association, Johnson & Johnson (NYSE: JNJ) has requested a ruling that the agreement and plan of merger between Merck & Co., Inc., and Schering-Plough Corporation constitutes a change of control that would permit the termination of the agreements between Schering-Plough and Johnson & Johnson's subsidiary Centocor Ortho Biotech Inc., regarding the product REMICADE(R) (infliximab), a well-established biologic product for inflammatory/immunological diseases, and SIMPONI(TM) (golimumab), a next-generation treatment. The termination of the agreements would return full rights to Johnson & Johnson for the distribution of these products in markets outside the United States where Schering-Plough currently has the rights to distribute these products.

"As its public statements have made clear, Merck is acquiring Schering-Plough," the company said. "The acquisition constitutes a change of control that triggers the right of our Centocor Ortho Biotech subsidiary to terminate the agreements."

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 119,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.


'/>"/>
SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Boston Scientific Announces Two Directors Leave Board as Burns Named CEO of Xerox and Johnson Confirmed as Under Secretary of Energy
2. Champions Shawn Johnson & Phil Jackson Wear Energy Muse Jewelry
3. Johnson & Johnson to Participate in Deutsche Bank 34th Annual Health Care Conference
4. Johnson & Johnson to Host Analyst Conference Call To Review Six-Month Trial Results From NEVO RES I
5. EF Johnson Technologies, Inc. Announces First Quarter 2009 Financial Results
6. Johnson & Johnson to Participate in Bank of America and Merrill Lynch 2009 Health Care Conference
7. Weill Cornell and Cornells Johnson School present first annual business and medicine symposium
8. Johnson & Johnson to Webcast Annual Meeting of Shareholders
9. Johnson & Johnson Reports 2009 First-Quarter Results:
10. Trust for Americas Health Supports Recommendations from Robert Wood Johnson Foundation Commission to Build a Healthier America
11. Practice Greenhealth Enters Partnership with Johnson & Johnson for Health Care Sustainability Research and Training
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... Long Beach, CA (PRWEB) , ... June 25, 2016 , ... ... from UCLA with Magna Cum Laude and his M.D from the David Geffen School ... San Diego and returned to Los Angeles to complete his fellowship in hematology/oncology at ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of ... recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at Work ... Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary ... Dallas that it will receive two significant new grants to support its work ... marked its 25th anniversary by recognizing patients, medical professionals and scientists for their ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016 The Academy of ... recommendations that would allow biopharmaceutical companies to ... entities that make formulary and coverage decisions, a move ... of new medicines. The recommendations address restrictions ... appear on the drug label, a prohibition that hinders ...
(Date:6/24/2016)... , June 24, 2016   Pulmatrix, Inc ... company developing innovative inhaled drugs, announced today that it ... Russell Investments reconstituted its comprehensive set of U.S. ... "This is an important milestone for Pulmatrix," said ... increase shareholder awareness of our progress in developing drugs ...
(Date:6/23/2016)... , June 23, 2016 Any dentist who ... challenges of the current process. Many of them do not ... the technical difficulties and high laboratory costs involved. And those ... offer it at such a high cost that the majority ... Dr. Parsa Zadeh , founder of Dental ...
Breaking Medicine Technology: